Brief: Sinomab Bioscience Says NMPA Nods IND For Drug For Neuromyelitis Optica Spectrum Disorder
09/06/2022 09:24
June 9 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* IND FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER ACCEPTED BY
CENTER FOR DRUG EVALUATION OF NMPA
Source text for Eikon: ID:nHKS37KGJq
Further company coverage: 3681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience